RedHill Biopharma has announced that opaganib, its therapeutic candidate for gastrointestinal acute radiation syndrome (GI-ARS), has been awarded an additional $1.7 million in funding from the US government. The funding comes in the form of a Small Business Innovation Research (SBIR) grant to RedHill's development partner, Apogee Biotechnology Corporation. This grant will support the research and development of opaganib as a medical countermeasure for GI-ARS. The grant is in addition to a previously awarded multimillion-dollar contract from the US government for the development of opaganib for ARS. Opaganib is an oral, small molecule pill that is being developed for multiple indications, including COVID-19, acute respiratory distress syndrome (ARDS), oncology, and more.
Fri, 21 Jul 2023 11:00:00 GMT | PR Newswire